



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbalà
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millionig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Heidi L. Kraus
Edward W. Yee
Albert L. Ferro
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaton
Kimberly N. Reddick

Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Uhler
Rae Lynn Pengaman
Jane Shershenovich
Lawrence J. Carroll
George S. Bardmesser
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller
LuAnne M. Yuricek
John J. Figueroa
Ann E. Summerfield
Tiera S. Coston

Aric W. Ledford
Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaron L. Schwartz
Mary B. Tung
Katrina Y. Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Timothy A. Doyle
Jennifer R. Mahalingappa
Teresa A. Colella
Jeffrey S. Lundgren

Victoria S. Rutherford
Eric D. Hayes
Of Counsel
Kenneth C. Bass III
Evan R. Smith

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

November 24, 2003

WRITER'S DIRECT NUMBER:
(202) 772-8673
INTERNET ADDRESS:
JCOVERT@SKGF.COM

Art Unit To Be Assigned

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Re: U.S. Utility Patent Application
Appl. No. *To Be Assigned*; Filed: July 21, 2003 *10,622,581*
For: **Inhibitors of Copper-Containing Amine Oxidases**
Inventors: Smith *et al.*
Our Ref: 1708.0270002/JMC/RHD

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. 4 pages of Form PTO-1449 citing 12 documents;
3. First Supplemental Information Disclosure Statement;
4. 4 pages of Form PTO-1449 citing 15 documents;
5. Copy of document AR8; and
6. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
November 24, 2003
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


John M. Covert
Attorney for Applicants
Registration No. 38,759

JMC/RHD:cpn
Enclosures

::ODMA\MHODMA\SKGF_DC1;202956;1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Smith *et al.*

Appl. No. *To Be Assigned*

Filed: July 21, 2003

For: **Inhibitors of Copper-Containing
Amine Oxidases**

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 1708.0270002/JMC/RHD

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of the documents were cited by or submitted to the Office in an IDS that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/898,003, filed July 5, 2001, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of the documents are not attached. 37 C.F.R. § 1.98(d).

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following in regard to non-English language documents AS1 and AT4 cited on Form PTO 1449:

Document AS1, Grifantini *et al.*, *Il Farmaco Ed. Sci.* 23:197-203 (1968), purportedly discloses alkyl- and acyl-derivatives of N-amino-1-ephedrine and N-amino-*d*-

pseudoephedrine and the corresponding 4,5-dimethyl-6-phenyl-5,6-dihydro-4H-1,3,4-oxadiazine isomers. An English-language abstract of this publication appears on the first page of the document (page 197).

Document AT4, Takahashi *et al.*, *Yakugaku Zasshi* 101:1154-1156 (1981), purportedly discloses a number of N-alkylaminoephedrine derivatives having methyl, ethyl, isopropyl, and benzyl groups. An English-language abstract of this publication appears on the first page of the document (page 1154).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


John M. Covert
Attorney for Applicants
Registration No. 38,759

Date: Nov 24, 2003

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Smith *et al.*

Appl. No. *To Be Assigned*

Filed: July 21, 2003

For: **Inhibitors of Copper-Containing
Amine Oxidases**

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 1708.0270002/JMC/RHD

First Supplemental Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed herewith in connection with the above-captioned application. A copy of document AR8 is attached.

Copies of the documents AA1, AL1, AM1, and AR5-AT7 were cited by or submitted to the Office in an IDS that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/898,003, filed July 5, 2001, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Copies of documents AB1 and AC1 are not provided in accordance with the U.S. Patent and Trademark Office pre-OG notice of July 11, 2003, which states "[t]he Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003."

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following in regard to non-English language documents AS1, AS5 and AS6 cited on Form PTO-1449:

Document AS1, Grifantini, M. *et al.*, *Il Farmaco Ed. Sci.* 23:197-203, (1968), cited in Applicants' Information Disclosure Statement filed on January 24, 2002, is in the Italian language. An English language abstract of document AS1 is attached as document AR7.

Document AS5, Ioffe, B.F., and Potekhin, A.A., *Tetrahedron Lett.* 36:3505-3508 (1967) is in German language. An English language abstract of document AS5 is attached as document AS7.

Document AS6, Schmitz, E., *et al.*, *Liebigs Ann. Chem.* 1043-1046 (1983) is in the German language. An English language abstract of document AS6 appears on the first page of the document (page 1043).

Document AT4, Takahashi, H., *et al.*, *Yakugaku Zasshi* 101:1154-1156 (1981), cited in Applicants' Information Disclosure Statement filed on January 24, 2002, is in the Japanese language. An English language abstract of document AT4 is attached as document AT7.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.


Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This First Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


John M. Covert
Attorney for Applicants
Registration No. 38,759

Date: Nov. 24, 2003

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1708.0270002/JMC/RHDAPPLICATION NO.
To Be AssignedAPPLICANT
Smith et al.FILING DATE
July 21, 2003GROUP
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>1</u>	Arvilommi, A.-M., et al., "Lymphocyte binding to vascular endothelium in inflamed skin revisited: a central role for vascular adhesion protein-1 (VAP-1)," <i>Eur. J Immunol.</i> 26:825-833, VCH Verlagsgesellschaft mbH (1996).
	AS	<u>1</u>	Grifantini, M., et al., "Derivati Delle N-Ammino-1-Efedrina E N-Ammino-d-Pseudoefedrina Ad Attivita Antidepressiva," <i>Il Farmaco Ed. Sci.</i> 23: 197-203, Il Farmaco (1968).
	AT	<u>1</u>	Lizcano, J.M., et al., "Inhibition of Bovine Lung Semicarbazide-Sensitive Amine Oxidase (SSAO) by Some Hydrazine Derivatives," <i>Biochem. Pharmacol.</i> 52:187-195, Elsevier Science (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 1708.0270002/JMC/RHD	APPLICATION NO. To Be Assigned
	APPLICANT Smith et al.	
	FILING DATE July 21, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Lyles, G.A., "Mammalian Plasma and Tissue-bound Semicarbazide-sensitive Amine Oxidases: Biochemical, Pharmacological and Toxicological Aspects," <i>Int. J. Biochem. Cell Biol.</i> 28:259-274, Pergamon Press (1996).
	AS	2	Salmi, M. and Jalkanen, S., "A 90-Kilodalton Endothelial Cell Molecule Mediating Lymphocyte Binding in Humans," <i>Science</i> 257:1407-1409, American Association for the Advancement of Science (1992).
	AT	2	Salmi, M. and Jalkanen, S., "Human Vascular Adhesion Protein 1 (VAP-1) Is a Unique Sialoglycoprotein that Mediates Carbohydrate-dependent Binding of Lymphocytes to Endothelial Cells," <i>J. Exp. Med.</i> 183:569-579, Rockefeller University Press (1996).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1708.0270002/JMC/RHD	APPLICATION NO. To Be Assigned
	APPLICANT Smith et al.	
	FILING DATE July 21, 2003	GROUP To Be Assigned


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	3	Salmi, M., et al., "Induction and Function of Vascular Adhesion Protein-1 at Sites of Inflammation," J. Exp. Med. 178:2255-2260, Rockefeller University Press (1993).
	AS	3	Salmi, M., et al., "Homing of Mucosal Leukocytes to Joints. Distinct Endothelial Ligands in Synovium Mediate Leukocyte-subtype Specific Adhesion," J. Clin. Invest. 99:2165-2172, American Society for Clinical Investigation (1997).
	AT	3	Salmi, M., et al., "Vascular Adhesion Protein 1 (VAP-1) Mediates Lymphocyte Subtype-specific, Selectin-independent Recognition of Vascular Endothelium in Human Lymph Nodes," J. Exp. Med. 186:589-600, Rockefeller University Press (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1708.0270002/JMC/RHD	APPLICATION NO. To Be Assigned
	APPLICANT Smith et al.	
	FILING DATE July 21, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>4</u>	Salmi, M., et al., "A Cell Surface Amine Oxidase Directly Controls Lymphocyte Migration," <i>Immunity</i> 14:265-276, Cell Press (March 2001).
	AS	<u>4</u>	Smith, D.J., et al., "Cloning of Vascular Adhesion Protein 1 Reveals a Novel Multifunctional Adhesion Molecule," <i>J. Exp. Med.</i> 188:17-27, Rockefeller University Press (1998).
	AT	<u>4</u>	Takahashi, H., et al., "Synthesis of N-Alkylaminoephedrine and Their Effect on Bronchial Musculature," <i>Yakugaku Zasshi</i> 101:1154-1156, Pharmaceutical Society of Japan (1981).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



FORM PTO-1449 <u>FIRST SUPPLEMENTAL</u> <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1708.0270002/JMC/RHD	APPLICATION NO. To Be Assigned
	APPLICANT Smith et al.	
	FILING DATE July 21, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	3,377,345	04/09/1968	Trepanier et al.			09/23/1966
	AB1	2003/0125360 A1	07/03/2003	Smith et al.			07/12/2001
	AC1	6,624,202 B2	09/23/2003	Smith et al.			07/05/2001
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 93/23023 A1	11/25/1993	WIPO			Yes No
	AM1	WO 02/02090 A3	01/10/2002	WIPO			Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	<u>5</u>	Graser, G., et al., "Incorporation of chirally deuterated putrescines into Pyrrolizidine Alkaloids: A Reinvestigation," <i>Phytochemistry</i> 47:1017-1024, Elsevier Science, Ltd. (1998)	
AS	<u>5</u>	Ioffe, B.V., and Potekhin, A.A., "Uber eine neue art von ring-ketten-tautomerie und die einfachsten tetrahydro-1,3,4-oxadiazinderivate," <i>Tetrahedron Lett.</i> 36:3505-3508, Pergamon Press, Ltd. (1967)	
AT	<u>5</u>	Potekhin, A.A., and Zaitsev, B.D., "Ring-chain Tautomerism of Substituted Hydrazones II. Derivatives of 1-hydrazino- and 1-(N-alkylhydrazino)-2-propanols," <i>Chemistry of Heterocyclic Compounds</i> 7:277-283, Plenum Publishing Corporation (1971)	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1708.0270002/JMC/RHD	APPLICATION NO. To Be Assigned
	APPLICANT Smith et al.	
	FILING DATE July 21, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	<u>6</u>	Potekhin, A.A., and Bogan'kova, E.A., "Ring-chain Tautomerism of Substituted Hydrazones VII. Substituted 4-tert-butylperhydro-1,3,4-oxadiazines," <i>Chemistry of Heterocyclic Compounds</i> 9:1321-1326, Plenum Publishing Corporation (1973)	
AS	<u>6</u>	Schmitz, E., et al., "Versuche zur N-Aminierung von Alkaloiden," <i>Liebigs Ann. Chem.</i> 1043-1046, Verlag Chemie GmbH (1983)	
AT	<u>6</u>	Trepanier, D.L., et al., "Synthesis and Pharmacological Evaluation of Some Tetrahydrooxadiazinones and Some Dihydroaminooxadiazines," <i>J. Med. Chem.</i> 11:357-360, Mack Printing Company (1968)	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1708.0270002/JMC/RHD	APPLICATION NO. To Be Assigned
	APPLICANT Smith et al.	
	FILING DATE July 21, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	7	CAplus, Accession No. 1968:426896, CAplus English language abstract for Grifantini, M. et al., "Derivatives of N-amino-1-ephedrine and N-amino-d-pseudoephedrine having antidepressive activity," <i>Il Farmaco Ed. Sci.</i> 23:197-203, <i>Il Farmaco</i> (1968) (Document AS1 cited in Applicants' IDS filed January 24, 2002)
	AS	7	CAplus, Accession No. 1968:78260, CAplus English language abstract for Ioffe, B.V., and Potekhin, A.A., "New type of ring-chain tautomerism and the simplest tetrahydro-1,3,4-oxadiazine derivatives," <i>Tetrahedron Lett.</i> 36:3505-3508, Pergamon Press, Ltd. (1967) (Document AS5)
	AT	7	CAplus, Accession No. 1982:142348, CAplus English language abstract for Takahashi, H., et al., "Synthesis of N-alkylaminoephedrine and their effect on bronchial musculature," <i>Yakugaku Zasshi</i> 101:1154-1156, Pharmaceutical Society of Japan (1981) (Document AT4 cited in Applicants' IDS filed January 24, 2002)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1708.0270002/JMC/RHD	APPLICATION NO. To Be Assigned
	APPLICANT Smith et al.	
	FILING DATE July 21, 2003	GROUP To Be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	8	Database CAPLUS, Accession No. 1991:526442, Document No. 115:126442, Abstract of Hoogenboom, L.A., et al., "Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone," Food Chem. Toxicol. 29:185-191 (1991), American Chemical Society (1991)
	AS		
	AT		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.